Dennis Vargo

1.2k total citations
29 papers, 610 citations indexed

About

Dennis Vargo is a scholar working on Hematology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dennis Vargo has authored 29 papers receiving a total of 610 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 9 papers in Genetics and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dennis Vargo's work include Erythropoietin and Anemia Treatment (13 papers), Hemoglobinopathies and Related Disorders (9 papers) and Renal cell carcinoma treatment (5 papers). Dennis Vargo is often cited by papers focused on Erythropoietin and Anemia Treatment (13 papers), Hemoglobinopathies and Related Disorders (9 papers) and Renal cell carcinoma treatment (5 papers). Dennis Vargo collaborates with scholars based in United States, Canada and Germany. Dennis Vargo's co-authors include D. Craig Brater, William G. Kramer, Paula Black, William B. Smith, Blaine Y. Takesue, William M. Tierney, Lisa E. Harris, Clement J. McDonald, J. Marc Overhage and Michael D. Murray and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of the American Society of Nephrology.

In The Last Decade

Dennis Vargo

28 papers receiving 574 citations

Peers

Dennis Vargo
Daphne H. Knicely United States
James C. Coons United States
Heidi S. Wirtz United States
Yuka Kiyota United States
David Campen United States
Dylan Steen United States
Suehyun Lee South Korea
Gerald Levy United States
Irfan Khan United States
Robin Boineau United States
Daphne H. Knicely United States
Dennis Vargo
Citations per year, relative to Dennis Vargo Dennis Vargo (= 1×) peers Daphne H. Knicely

Countries citing papers authored by Dennis Vargo

Since Specialization
Citations

This map shows the geographic impact of Dennis Vargo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dennis Vargo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dennis Vargo more than expected).

Fields of papers citing papers by Dennis Vargo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dennis Vargo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dennis Vargo. The network helps show where Dennis Vargo may publish in the future.

Co-authorship network of co-authors of Dennis Vargo

This figure shows the co-authorship network connecting the top 25 collaborators of Dennis Vargo. A scholar is included among the top collaborators of Dennis Vargo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dennis Vargo. Dennis Vargo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sarnak, Mark J., Rajiv Agarwal, Neil Boudville, et al.. (2023). Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. Nephrology Dialysis Transplantation. 38(10). 2358–2367. 6 indexed citations
2.
Agarwal, Rajiv, Sanjeev Anand, Kai‐Uwe Eckardt, et al.. (2022). Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials. American Journal of Nephrology. 53(10). 701–710. 5 indexed citations
3.
Parfrey, Patrick S., et al.. (2021). Thromboembolic Events with Vadadustat vs. Darbepoetin Alfa for Anemia Treatment in Patients with Dialysis-Dependent CKD. Journal of the American Society of Nephrology. 32(10S). 184–184. 1 indexed citations
4.
Winkelmayer­, Wolfgang C., Steven Fishbane, James A. Tumlin, et al.. (2021). Iron-Related Outcomes in Patients with Dialysis-Dependent CKD Randomized to Vadadustat vs. Darbepoetin Alfa. Journal of the American Society of Nephrology. 32(10S). 182–182. 1 indexed citations
5.
Chertow, Glenn M., Neil Boudville, Carlos González, et al.. (2021). Vadadustat for Treatment of Anemia in Patients with Dialysis-Dependent CKD Receiving Peritoneal Dialysis. Journal of the American Society of Nephrology. 32(10S). 184–184. 1 indexed citations
6.
McCullough, Peter A., Wei Luo, Robert A. Anders, Dennis Vargo, & Patrick S. Parfrey. (2021). Assessment of Thromboembolic Events with Vadadustat vs. Darbepoetin Alfa for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD. Journal of the American Society of Nephrology. 32(10S). 184–184. 1 indexed citations
7.
Koury, Mark J., Pablo E. Pérgola, Prabir Roy‐Chaudhury, et al.. (2021). Iron-Related Outcomes in Patients with Non-Dialysis-Dependent CKD Randomized to Vadadustat vs. Darbepoetin Alfa. Journal of the American Society of Nephrology. 32(10S). 190–190. 1 indexed citations
8.
Winkelmayer­, Wolfgang C., James A. Tumlin, Steven Fishbane, et al.. (2021). MO539HEMATOLOGIC EFFICACY OF VADADUSTAT FOR ANEMIA IN PATIENTS WITH KIDNEY FAILURE ON DIALYSIS. Nephrology Dialysis Transplantation. 36(Supplement_1).
9.
Agarwal, Rajiv, et al.. (2021). Vadadustat, an Oral HIF-PHI, Is Not Associated with Increased Risk of Neoplasm in Patients with Anemia due to CKD. Journal of the American Society of Nephrology. 32(10S). 183–184. 1 indexed citations
10.
Eckardt, Kai‐Uwe, Rajiv Agarwal, Youssef M.K. Farag, et al.. (2020). Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation. 36(11). 2039–2048. 20 indexed citations
11.
Cotreau, Monette, et al.. (2013). The effect of food on the pharmacokinetics of tivozanib hydrochloride. Clinical Pharmacology in Drug Development. 3(2). 158–162. 5 indexed citations
12.
13.
Cotreau, Monette, et al.. (2012). Abstract 752: The effect of food on the pharmacokinetics of tivozanib. Cancer Research. 72(8_Supplement). 752–752. 3 indexed citations
14.
Song, Minho, et al.. (2000). Comparison of Zafirlukast (Accolate®) Absorption After Oral and Colonic Administration in Humans. Pharmaceutical Research. 17(2). 154–159. 21 indexed citations
15.
Fleming, Kirsten, et al.. (1997). The neurocognitive effects of quetiapine (‘seroquel’, ICI 204, 636). Schizophrenia Research. 24(1-2). 197–197. 6 indexed citations
16.
Tierney, William M., Blaine Y. Takesue, Dennis Vargo, & Xiao‐Hua Zhou. (1996). Using electronic medical records to predict mortality in primary care patients with heart disease. Journal of General Internal Medicine. 11(2). 83–91. 21 indexed citations
17.
Vargo, Dennis, D. Craig Brater, David W. Rudy, & Suzanne K. Swan. (1996). Dopamine does not enhance furosemide-induced natriuresis in patients with congestive heart failure.. Journal of the American Society of Nephrology. 7(7). 1032–1037. 19 indexed citations
18.
Tierney, William M., J. Marc Overhage, Blaine Y. Takesue, et al.. (1995). Computerizing Guidelines to Improve Care and Patient Outcomes: The Example of Heart Failure. Journal of the American Medical Informatics Association. 2(5). 316–322. 185 indexed citations
19.
Vargo, Dennis, et al.. (1995). Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure*. Clinical Pharmacology & Therapeutics. 57(6). 601–609. 206 indexed citations
20.
Vargo, Dennis, et al.. (1994). The pharmacodynamics of torsemide in patients with congestive heart failure. Clinical Pharmacology & Therapeutics. 56(1). 48–54. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daphne H. Knicely Breakdown of academic impact, for papers by James C. Coons Breakdown of academic impact, for papers by Heidi S. Wirtz Breakdown of academic impact, for papers by Yuka Kiyota Breakdown of academic impact, for papers by David Campen Breakdown of academic impact, for papers by Dylan Steen Breakdown of academic impact, for papers by Suehyun Lee Breakdown of academic impact, for papers by Gerald Levy Breakdown of academic impact, for papers by Irfan Khan Breakdown of academic impact, for papers by Robin Boineau
Rankless by CCL
2026